# A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia

Source: https://onco.cc/trials/nct05865028/  
OnCo record `nct05865028` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of APG-157 run by Elizabeth J Franzmann, now recruiting.

## Summary

A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia is a phase 2 interventional study registered as NCT05865028 by Elizabeth J Franzmann, with 32 participants planned, started 2023-05-24. Conditions recorded: Oropharyngeal Dysplasia, Oral Cavity Dysplasia and Oral Carcinoma in Situ. Interventions recorded: APG-157.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05865028
- Phase: 2
- Setting: Phase II A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia
- Sponsor: Elizabeth J Franzmann
- Enrolled: 32

## Sources

- ClinicalTrials.gov NCT05865028: https://clinicaltrials.gov/study/NCT05865028

## Connected records

- cancers: [Oral cavity cancer (mouth and tongue)](https://onco.cc/cancers/oral-cavity-cancer/), [Oropharyngeal cancer (tonsil and base of tongue)](https://onco.cc/cancers/oropharyngeal-cancer/)
- drugs: [APG-157](https://onco.cc/drugs/apg-157/)
- companies: [Aveta Biomics](https://onco.cc/companies/aveta-biomics/)

---
JSON: https://onco.cc/api/v1/entities/nct05865028.json